SLU-PP-915
also ERR pan-agonist 915
SLU-PP-915 is a pan-ERR agonist from the lab that made SLU-PP-332. It is a chemically distinct thiophene boronic acid [1] and, unlike SLU-PP-332, it is orally bioavailable. In mice it improved aerobic exercise performance as much as SLU-PP-332 did [2] and protected the heart in a heart-failure model [3]. It has never been tested in humans.
The orally active version of the best-known exercise mimetic; still a mouse-only compound, and banned in sport.

- meta-analysis
- RCT
- trial
- observational
- preclinical / case
- review / patent / other
- retracted
- + Orally active in mice, unlike SLU-PP-332
- + Improved running distance and duration in mice
- + Improved heart function in a mouse heart-failure model
- − No human studies of any kind
- − Newest of the group; the smallest literature
- − Falls under WADA's exercise-mimetic ban
Overview
SLU-PP-915 came from a structure-based design program that started from known ERRγ agonists. That program produced a series of 2,5-disubstituted thiophenes, and replacing a phenol with a boronic acid kept their potency [1].
Its selling point over SLU-PP-332 is oral activity. SLU-PP-332 lacks oral bioavailability. SLU-PP-915 improved running distance and duration by about as much when injected, and kept comparable efficacy when taken orally once blood levels were accounted for [2]. In a pressure-overload heart failure model it improved ejection fraction, reduced fibrosis and increased survival, alongside SLU-PP-332 [3].
Mechanism
Like SLU-PP-332, it activates the ERRs, which control mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation and the Krebs cycle. It induces Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding treadmill running [2]. In the heart the benefit ran mainly through ERRγ [3].
- ERRα / ERRβ / ERRγ nuclear receptorsactivatespotent pan-ERR agonist designed from an ERRγ template [1]strong
- Aerobic exercise gene programactivatesinduces the exercise gene Ddit4 at or above treadmill-running levels [2]moderate
Safety
risks and cautions, not medical adviceThere is no human safety data. The animal literature reports no evident toxicity in obesity models, and clinical trials are still needed [4]. In human liver preparations it formed seven phase I metabolites and no phase II conjugates. Anti-doping laboratories characterised these because of its doping potential [5].
- None established; no human exposure has been studied
- Exercise mimetics are prohibited in sport by WADA [6]
- Not approved; product identity and purity unverified; the boronic acid group is unusual in supplements
Interactions
documented pairs only, not exhaustive- SLU-PP-332cautionSame receptors, same mechanism; combining them duplicates one lever and has never been studied
FAQ
References
entry last reviewed 2026-09-18- [1]Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915.Hampton CS, Sitaula S, Billon C et al.Eur J Med Chem 2023preclinical · cellPMID 37421886◌ unreviewed
- [2]An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity.Billon C, Appourchaux K, Côté I et al.J Pharmacol Exp Ther 2026preclinical · animalPMID 41421047◌ unreviewed
- [3]Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.Xu W, Billon C, Li H et al.Circulation 2024preclinical · animalPMID 37961903◌ unreviewed
- [4][Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].de Souza-Lima J, Astrosa-Martin BD, Galaz-Rodríguez CA et al.Rev Med Chil 2026reviewPMID 42024694in Spanish◌ unreviewed
- [5]In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential.Möller T, Krug O, Thevis MRapid Commun Mass Spectrom 2026preclinical · cellPMID 41588687◌ unreviewed
- [6]Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.Avliyakulov NK, Sobolevsky T, Ahrens EDrug Test Anal 2026preclinical · cellPMID 41688415◌ unreviewed